Navigation Links
announces in Medical Technology

NewCardio Announces Master Services Agreement With Dedicated Phase I

SANTA CLARA, Calif., Aug. 5 /PRNewswire-FirstCall/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, today announced that Dedicated Phase I, an innovative, Phoenix, Arizona-based provider of clinical research services including a Core ECG...

Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)

THOUSAND OAKS, Calif., Aug. 3 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN ) today announced positive top-line results from a pivotal Phase 3 head-to-head trial evaluating denosumab administered subcutaneously versus Zometa((R)) (zoledronic acid) administered as an intraveno...

Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome

PALO ALTO, Calif., Aug. 3 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK ) today announced that the positive results from a Phase 1 multicenter, dose escalation study of ezatiostat hydrochloride (TELINTRA, TLK199) tablets in patients with Myelodysplastic Syndrome (MDS) have been p...

Cryo-Cell Announces C'elle(SM) Research and Development Collaboration with Cryopraxis Cryobiology Ltd.

Oldsmar, Fla., July 27 /PRNewswire-FirstCall/ --Cryo-Cell International, Inc. (OTC Bulletin Board: CCEL), one of the largest and most established leaders in stem cell innovation today announced a research and development collaboration agreement with Cryopraxis Cryobio...

NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study

SAN MATEO, Calif., July 24 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX ) announced today the preliminary results of a short-term clinical study (Study C123) of Qutenza(TM) in patients with postherpetic neuralgia (PHN) following pretreatment with an FDA-approved topical anestheti...

Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma

KENILWORTH, N.J., July 22 /PRNewswire-FirstCall/ -- Schering-Plough today announced that a New Drug Application (NDA) for a fixed-dose combination of mometasone furoate and formoterol fumarate has been filed in the United States and accepted for review by the U.S. Food and Drug Administration...

Cardica Announces Publication of Pivotal PAS-Port(R) Proximal Anastomosis System Clinical Trial Results

REDWOOD CITY, Calif., July 22 /PRNewswire-FirstCall/ -- Cardica, Inc. (Nasdaq: CRDC ) today announced that the full results of the PAS-Port system multi-center pivotal trial, known as the EPIC trial, were published in the July issue of the peer-reviewed publication The J ournal ...

Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing

SOUTH SAN FRANCISCO, Calif., July 21 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on innovative oncology therapies, today announced results from a Phase 1 cardiac safety study of picoplatin, a new generation platinum-...

AlphaVax Announces Results from Initial Testing of Its H1N1 (Swine) Influenza Vaccine

RESEARCH TRIANGLE PARK, N.C., July 17 /PRNewswire/ -- AlphaVax, Inc. announced today that it has completed process development and preclinical immunogenicity studies of its H1N1 (swine) influenza vaccine and will manufacture clinical trial material by the end of the month. This vaccin...

Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences

CORK, Ireland, July 16 /PRNewswire/ --Tibotec Pharmaceuticals today announced that it has entered into a license and collaboration agreement with Gilead Sciences, Inc. for the development and commercialization of a new once-daily fixed-dose antiretroviral product containing Tibotec's inv...

Oncolytics Biotech(R) Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC

CALGARY, July 16 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY ) ('Oncolytics') reported today that Dr. Shizuko Sei et al. published the results of their work examining reovirus and chemotherapy against human non-small cell lung cancer (NSCLC). The paper, entitled "Syn...

Elbit Imaging Ltd. Announces - Swiss Team Uses InSightec's ExAblate(R) 4000 Brain System to Treat Patients With Functional Brain Disorders

TEL AVIV, Israel, July 14 /PRNewswire-FirstCall/ -- Elbit Imaging Ltd. (TASE: EMIT, Nasdaq: EMITF ), announced today that, its subsidiary (in which EI holds indirectly approximately 58.34%, InSightec Ltd., announced today that a team at the University Children's Hospital Zurich has completed...

Sirius Genomics Announces New Collaboration with Assistance Publique-Hopitaux de Paris

VANCOUVER, July 13 /PRNewswire/ - Sirius Genomics, a developer of pharmacogenomic diagnostics, announced today that it has signed a collaborative agreement with the Assistance Publique-Hopitaux de Paris (AP-HP) to study genomic correlations in severe sepsis patients. The agreement focuses on the c...

Relievant Medsystems Announces Completion of $20 Million Financing

REDWOOD CITY, Calif., July 7 /PRNewswire/ -- Relievant Medsystems, Inc., developer of a novel, minimally invasive treatment for chronic low back pain, reported today that it has completed a $20 million private equity financing. The financing was led by Morgenthaler Ventures with existing investor...

Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled

SAN DIEGO, June 30 /PRNewswire/ -- Accumetrics, Inc. announces that it has reached the halfway mark (1,600 patients) in the enrollment of its landmark clinical trial, GRAVITAS ( G auging R esponsiveness with A V erifyNow(R) Assay I mpact on T hrombosis A nd S afety). The trial is specifical...

Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections

SAN DIEGO, June 30 /PRNewswire/ -- Calixa Therapeutics Inc. today announced the initiation of a Phase 2 clinical trial of CXA-101 in patients with complicated urinary tract infections. CXA-101 is a new broad-spectrum, parenteral cephalosporin antibiotic with excellent in vitro and in vivo act...

AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain

Study in major abdominal surgery patients achieved primary and secondary endpoints REDWOOD CITY, Calif., June 29 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. today announced positive results from the second Phase 2 clinical study evaluating the safety and efficacy of its ARX-01 Sufentanil Nan...

Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech

RICHMOND, Calif., June 29 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today announced that a key research milestone has been achieved in its Research and License Agreement with Genentech, Inc., a wholly-owned member of the Roche Group, for the generation of cell lines wit...

Innovative Psoriasis Treatment PSORENT(R) Announces Healthcare Cost Savings Potential Consistent with President Obama's Announcement on Healthcare Reform

PRINCETON, N.J., June 25 /PRNewswire/ -- "Congratulations President Obama on your agreement with large pharmaceutical companies to cut prescription costs for the elderly," says Mark D. Steele, president of NeoStrata Company, Inc. "We thought you should know that you have a little company in New Je...

ALP Life Sciences, LLC Announces Nanoveson(TM) Patent Filing and Whitepaper Availability on Proposed Therapy for Non-Alcoholic Fatty Liver Disease (NAFLD) and Comorbid Diseases

BLACK MOUNTAIN, N.C., June 24 /PRNewswire/ -- ALP Life Sciences, LLC (Company) today announced the Nanoveson(TM) patent has been filed and the Nanoveson(TM) whitepaper is available at www.ALPLifeSciences.com/wp . After completing initial research, the Company is pursuing clinical trials an...

Spherix Announces Positive Phase 2 Study Results

Preliminary Data Demonstrates Reduction of HbA1c Levels With Doses an Order of Magnitude Lower than the Dose Used in the Current Phase 3 Trial. BETHESDA, Md., June 24 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq CM: SPEX), an innovator in biotechnology for diabetes therapy, and a pr...

Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies

--Integrated human AME studies comply with recent FDA guidance for earlier testing-- PRINCETON, N.J., June 23 /PRNewswire/ -- Covance Inc. today announced its integrated radiolabeled clinical pharmacology studies in compliance with Food and Drug Administration (FDA) guidance on Metabol...

GeoVax Labs, Inc. Announces Results of 2009 Annual Shareholders Meeting

ATLANTA, June 23 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based biopharmaceutical company developing human vaccines for diseases caused by the HIV-1 (Human Immunodeficiency Virus), and other infectious agents, today announced the results of its Annual Sh...

CoAxia, Inc. Announces $21.5M Series D Financing

Funding and Clinical Trial Progress Position Company for PMA Submission MINNEAPOLIS, June 22 /PRNewswire/ -- CoAxia, Inc. of Maple Grove, MN, announced today completion of a $21.5M Series D financing. The round was led by Sofinnova Partners with participation from all previous major investors...

Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs

LIBERTYVILLE, Ill., June 18 /PRNewswire-USNewswire/ -- Families of Spinal Muscular Atrophy has just released details of the latest developments for the Families of SMA funded therapeutic pipeline. Families of SMA is currently funding three distinct drug discovery programs: 1) Quinazolines to ...

Roskamp Institute Announces Enrollment of First Students to Participate in its Innovative Research Doctorate Program

Florida's First Three-Year Neuroscience Research Doctorate Program SARASOTA, Fla., June 18 /PRNewswire/ -- Sarasota's Roskamp Institute (Roskamp) today announced the first enrollment of students in its pioneering three-year Ph.D. program through which students will conduct full-time laborator...

CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Advanced Breast Cancer

- 12 week progression free rate supports advancement into second stage of Simon 2-Stage designed trial - BRANFORD, Conn., June 17 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN ) announced today that its Phase I/II Trial evaluating CR011-vcMMAE for the treatment of patients w...

ThermoGenesis Announces National Institute of Health Grant

COMPANY'S FIRST-EVER NIH GRANT WILL BE USED TO DEVELOP CELL DELIVERY TECHNOLOGIES FOR REGENERATIVE MEDICINE APPLICATIONS RANCHO CORDOVA, Calif., June 9 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL ), a leading supplier of innovative products for processing and storing adult s...

ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease

IRVINE, Calif., June 8 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today announced positive results from a proof-of-concept Phase 2 clinical study in subjects with dry eye disease (keratoconjuctivitis sicca) using a new, proprietary, low-dose formulation of bromfenac, t...

Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections

Second Generation Oxazolidinone Demonstrates Safety and Efficacy with Once-Daily, 200 milligrams (mg) Dosing over Five to Seven Days of Treatment SAN DIEGO, June 8 /PRNewswire/ -- Trius Therapeutics, Inc. today announced results from its Phase 2 clinical trial evaluating the safety and effic...

Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting

--First of 2 data sets to be released-- PARIS, June 8 /PRNewswire/ -- Results from two randomized, active-controlled clinical trials in patients with blepharospasm and cervical dystonia -- one placebo-controlled spasticity trial and one upper limb spasticity trial -- were presented at the ...

Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes

NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) announced today new, positive Phase II study results of LY2189265, its investigational glucagon-like peptide 1 (GLP-1) analog administered subcutaneously once-weekly for the treatment of type 2 diabetes. These data ...

Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk

- Late-Breaking Data from Pivotal BLOOM Trial Presented at the American Diabetes Association's 69th Scientific Sessions Expand on Previously Announced Positive Top-Line Results - NEW ORLEANS, June 6, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced today...

Access Pharmaceuticals Announces Publication of Thiarabine Combination Data

Combined with Clofarabine, Thiarabine Achieves High Cure Rate in a Colorectal Cancer Model DALLAS, June 4 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), announced today that new Thiarabine preclinical efficacy data will shortly be published demo...

Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting

IRVINE, Calif., June 4 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (Pink Sheets: CGCP) the market leader in laser transmyocardial revascularization (TMR) for the treatment of chronic cardiac ischemia, announces that Dr. Naresh Trehan of New Delhi will be presenting his clinical results of ...

Advanced Life Sciences Announces Outcome of FDA's Anti-Infective Drugs Advisory Committee Review of Restanza(TM) (cethromycin)

CHICAGO, June 2 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS) announced today that the FDA's Anti-Infective Drugs Advisory Committee voted in the majority that Restanza(TM) (cethromycin) demonstrated safety for the outpatient treatment of adults with m...

Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients

-- Findings Presented at American Society of Clinical Oncology 2009 Annual Meeting and Included in Best of ASCO(R) Educational Program -- SAN FRANCISCO, June 2 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN ) today announced the presentation of new clinical results from a Phase 1-...

Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW

New Insights into the Prediction of IBD Using Serology Testing Also Presented SAN DIEGO, June 2 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced new findings regarding a correlation between an important serologic marker used in the det...

Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Association's 69th Scientific Sessions

- Late-Breaking Abstract Accepted - SAN DIEGO, June 1, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced today that a late-breaking abstract of its lorcaserin Phase 3 BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) tr...

Neurobiological Technologies' Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program

EMERYVILLE, Calif., June 1 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII ) (NTI(R)) today announced that Celtic Pharmaceutical Holdings L.P. (Celtic Pharma) has announced the results from its Phase 3 Clinical Program for XERECEPT(R) in patients with edema associated ...
Other Tags
(Date:9/15/2014)... digestion to disease resistance. Despite the fact that tropical ... planet, more is known about belly-button bacteria than bacteria ... working on Panama,s Barro Colorado Island discovered that small ... more than 400 different kinds of bacteria. The combined ... different kinds. , Bacteria in tropical forests may also ...
(Date:9/15/2014)... indicates that lowland tapir populations may continue to drop ... Researchers from the Office National de la Chasse et ... Diego Zoo Global reviewed data retrieved from camera traps ... years and compared this data to current harvest rates ... hunting tapirs in French Guiana," said Matthias Tobler, a ...
(Date:9/15/2014)... epilepsy drug to a morphine regimen can result in ... combination can reduce the dosage of the opioid needed ... researchers at Indiana University. , The result could bring ... difficult-to-treat condition often felt in the arms and legs ... a huge unmet need for better treatments for neuropathic ...
Breaking Biology News(10 mins):Smithsonian scientists discover tropical tree microbiome in Panama 2IU study: Combining epilepsy drug, morphine can result in less pain, lower opioid doses 2
(Date:9/16/2014)... For patients with locally advanced pancreatic cancer, the ... may be a promising treatment option, ultimately allowing ... be an option, according to research presented today ... 56th Annual Meeting. , Surgery is the only ... adenocarcinoma (PDA), the most common type of pancreatic ...
(Date:9/16/2014)... The Pain Center of Arizona (TPC), ... has selected Analance ™, Ducen ’s BI ... TPC seeing hundreds of thousands of patients annually, the ... through “home grown” systems trying to piece together actionable ... “Our current tools were not scalable and, in ...
(Date:9/16/2014)... September 16, 2014 Cloud based ... Streaming (HLS) & UStream API’S to serve m3u8 streams ... feature for broadcasting live video events with hundreds of ... , The App Builder is known for making beautiful ... iOS, BlackBerry and Windows 8 and already over 100,000 ...
(Date:9/16/2014)... reduce the risk of heart disease or stroke, even ... part of the diet. , A study of ... from Monash University,s Department of Epidemiology and Preventive Medicine ... consumption of dairy foods had played in the country,s ... dominantly Chinese food culture, unaccustomed to dairy foods, consuming ...
(Date:9/16/2014)... workers die in motor vehicles than any other workplace ... to address at an international conference being hosted by ... Queensland (CARRS-Q). , The Occupational Safety in Transport Conference ... September 18 and 19 brings together experts from all ... mining to improve workplace health and safety. , CARRS-Q ...
Breaking Medicine News(10 mins):Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 2Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 3Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 4Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 2Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 3Health News:A heart-felt need for dairy food 2Health News:CARRS-Q Host International Transport Safety Conference 2
Other Contents